Noxafil (posaconazole) / Merck (MSD), Ligand  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Noxafil (posaconazole) / Merck (MSD)
2010-020832-20: P06356

Ongoing
3
96
Europe
SCH 56592 (POSACONAZOLE) Solution for Injection, 18 mg/mL, SCH 56592,
Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials, Schering-Plough Research Institute
This study is going to be conducted in heathy volunteers.
 
 
2018-000972-14: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded).

Not yet recruiting
3
224
Europe
Ambisome®, Sporanox®, Vfend®, NOXAFIL, Powder for solution for infusion, Capsule, Tablet, Ambisome®, Sporanox®, Vfend®, NOXAFIL
CHU DE POITIERS, DGOS, JASSEN, MSD-MERCK, PFIZER, ELIVIE, SOS-Oxygen, VIVISOL, ORHE PHARMA
Chronic Pulmonary Aspergillosis, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
 
 
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
IA-DUET, NCT04876716 / 2020-000627-40: Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Terminated
3
66
Europe
Azole, Voriconazole, isavuconazole, posaconazole, Anidulafungin, Ecalta
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Hemato-Oncologie voor Volwassenen Nederland
Invasive Aspergillosis
05/24
05/24
2019-004511-31: Prospective validation and clinical evaluation of a new posaconazole dosingregimen for children and adolescents with cystic fibrosis and Aspergillus infection.

Ongoing
2/3
135
Europe
Noxafil - oral suspension 40 mg/ml, Noxafil 100 mg, [NA], [na], Oral suspension, Gastro-resistant tablet, Noxafil - oral suspension 40 mg/ml, Noxafil 100 mg
Bambino Gesù Children's Hospital, IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, Innovative Medicines Initiative 2, European Union’s Horizon 2020
Cystic Fibrosis and Aspergillus Infection, Aspergillus infection in people with cystic fibrosis, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
cASPerCF, NCT04966234 / 2019-004511-31: A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection

Recruiting
2/3
135
Europe, RoW
Posaconazole 100 MG [Noxafil], gastro-resistant tablets Noxafil® 100 mg, Posaconazole 40 MG/ML, 105 ml Noxafil® 40 mg/ml oral suspension
Bambino Gesù Hospital and Research Institute, University of Exeter, Radboud University, Consorzio per Valutazioni Biologiche e Farmacologiche
Cystic Fibrosis, Aspergillosis
04/23
11/23

Download Options